Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Streptomycin sulfate
Drug ID BADD_D02072
Description Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.[A233325]
Indications and Usage For the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).
Marketing Status Prescription; Discontinued
ATC Code A07AA04; J01GA01
DrugBank ID DB01082
KEGG ID D01350
MeSH ID D013307
PubChem ID 19648
TTD Drug ID D0N0EQ
NDC Product Code 51671-0009
Synonyms Streptomycin | Streptomycine Panpharma | Streptomycin Grünenthal | Estreptomicina CEPA | Strepto-Hefa | Strepto Hefa | Estreptomicina Clariana | Estreptomicina Normon | Strepto-Fatol | Strepto Fatol | Streptomycin Sulfate | Streptomycin Sulfate (2:3) Salt | Streptomycin Sulphate
Chemical Information
Molecular Formula C42H84N14O36S3
CAS Registry Number 3810-74-0
SMILES CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O.CC 1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O.OS(= O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Amblyopia06.02.01.001--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Azotaemia20.01.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Deafness04.02.01.001--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Eosinophilia01.02.04.001--
Haemolytic anaemia01.06.03.002--Not Available
Leukopenia01.02.02.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Ototoxicity12.03.01.012; 04.03.01.004--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Vomiting07.01.07.003--
Abasia17.02.05.035; 08.01.02.007--Not Available
Renal impairment20.01.03.010--Not Available
The 1th Page    1    Total 1 Pages